Mannkind, Biotech mit Sitz in Kalifornien, hat angekündigt , dass David Kendall seinem Team als Chief Medical Officer beitreten und würde ...
MannKind Corp. buy melinda
Start price
09.03.18
/
50%
€2.46
Target price
10.09.18
€2.93
Performance (%)
-34.68%
End price
10.09.18
€1.61
Summary
This prediction ended on 10.09.18 with a price of €1.61. Massive losses of -34.68% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MannKind Corp. | 2.206% | 2.206% | -18.563% | -0.579% |
| iShares Core DAX® | -1.432% | 0.000% | 12.331% | 59.631% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.688% | 98.396% |
| iShares Nikkei 225® | 1.448% | 5.269% | 18.051% | 50.544% |
| iShares S&P 500 | 0.114% | -0.217% | 1.388% | 63.586% |
Comments by melinda for this prediction
In the thread MannKind Corp. diskutieren
Biotechnologie und medizinische SecteurRecherche
Termin
(Laufzeit überschritten)